Skip to Content

Meet our Management Team

  • Bill Enright

    Chief Executive Officer
    Mr. Enright currently serves as our President and CEO and is a member of our board of directors. He was first elected to our board of directors in June 2008. Mr. Enright brings more than 25 years of experience in a variety of positions within the life science and biotech industries. Prior to joining Altimmune, Mr. Enright spent six years with GenVec, Inc. (NASDAQ: GNVC) with increasing responsibilities culminating in the Head of Business Development. Mr. Enright was responsible for helping to build GenVec’s vaccine business including generating approximately $140 million of funding for vaccine-related initiatives and moving four vaccines into clinical development. Prior to GenVec, Mr. Enright was a self employed consultant providing business development and strategic marketing services to academic institutions and a number of small to mid-size life science companies. Prior to becoming a consultant, and after spending several years as a bench scientist at SUNY at Buffalo, Mr. Enright spent 12 years with Life Technologies, Inc., working in various licensing, business management, manufacturing and research roles. Mr. Enright received a Master of Arts in Biology from SUNY at Buffalo and a Master of Science in Business Management from Johns Hopkins University.
    • Scot Roberts, Ph.D.

      Chief Scientific Officer
      Dr. Roberts joined us in December 2012 and has nearly 20 years of senior technical leadership experience, most recently as Chief Scientific Officer at ImQuest BioSciences, Inc., where he was responsible for managing scientific operations as well as business development opportunities in cancer and antivirals. Dr. Roberts held key positions at Wellstat Biologics Corporation from August 1996 until October 2010, including Director of Research and Development where he was responsible for a portfolio of biologic candidates in oncology including a clinical stage asset. He also led bioassay development efforts for the company and assumed leadership roles in upstream process development and animal pharmacology while at Wellstat. Dr. Roberts has significant experience in both small molecule and biologics drug development with a focus on viral vectors and antiviral therapies. Dr. Roberts completed a post doctoral fellowship at the National Cancer Institute, Laboratory of Molecular Virology and has numerous patents and publications in peer-reviewed journals, and has been an invited speaker and Chair at numerous international conferences. Dr. Roberts received his Ph.D. from the Johns Hopkins School of Medicine, Department of Pharmacology and Molecular Sciences.
      • Elizabeth A. Czerepak

        Chief Financial Officer and Executive Vice President of Corporate Development
        Ms. Czerepak joined us in April 2015 as our Chief Financial Officer, and serves as Secretary of our board of directors. An experienced finance executive, Ms. Czerepak has led a broad range of initiatives at public and privately held pharmaceutical and biotechnology companies. As a venture capital investor and board member of several portfolio companies at Bear Stearns Health Innoventures (BSHI), she played a key role in raising hundreds of millions of dollars in private financings and IPOs, and the successful sale of two portfolio companies. From April 2014 until April 2015, Ms. Czerepak served as CFO and Chief Business Officer at Isarna Therapeutics BV and, earlier, from January 2011 until March 2014, as CFO and Principal Accounting Officer at Cancer Genetics, Inc. (NASDAQ: CGIX). Prior to CGIX, from April 2000 until June 2009, she was a founding general partner at BSHI, and from April 2000 until December 2008, she was a managing director and an NASD Registered Representative at JP Morgan Inc. and Bear Stearns & Co. Earlier in her career, Ms. Czerepak was Vice President of Business Development and a member of the U.S. executive board at BASF Pharma, and held senior-level finance, licensing and corporate development positions at Hoffmann-La Roche and Merck & Co. Ms. Czerepak has an MBA from Rutgers University and a BA magna cum laude from Marshall University.
        • Bertrand Georges, Ph.D.

          Chief Technology Officer
          Dr. Georges has 15 years expertise in the field of molecular & cellular immunology and T cell vaccine development. He was co-founder and Chief Technology Officer of Immune Targeting Systems (ITS) Limited from 2004 until its acquisition by us in March 2015. Prior to ITS, Dr. Georges held the position of head of immunology at SEDAC-Therapeutics from 1999 until 2003. Dr. Georges has significant experience in product formulation and manufacturing, preclinical and early clinical development with a focus on peptide-based vaccines. Dr. Georges has a special interest in designing vaccines against infectious diseases and cancer and has developed T cell epitope identification methodologies combining in silico, in vitro and in vivo approaches. He received his Ph.D. in Molecular Immunology from the Pasteur Institute and is the co-author of 18 publications and co-inventor of 11 patent families.
          • Sybil Tasker, M.D., FACP, FIDSA

            Chief Medical Officer
            Dr. Tasker joined the Company in April 2016, and is an experienced infectious disease clinician and fellow of the American College of Physicians and the Infectious Diseases Society of America. Prior to joining, she led development of a therapeutic herpes simplex vaccine at Genocea Biosciences and had positions of increasing responsibility in infectious disease product development strategy at two global CROs. A prior career military officer, she was the senior U.S. Navy infectious disease physician and technical advisor to Department of Defense leaders about a wide variety of infectious disease policy issues, including HIV, tropical disease, vaccination, infection control, bioterrorism and pandemic preparedness. She has extensive antimicrobial, vaccine and infectious disease related device and diagnostic development experience across all phases of the clinical development process. She holds a California medical license and is board certified in both internal medicine and infectious diseases. Dr. Tasker earned an A.B. degree in Biochemistry from Princeton University and an M.D. degree from Columbia University.
            • Ori Solomon, JD

              Outside General Counsel
              Ori is Outside General Counsel and a Partner at Proskauer Rose LLP in the Private Equity and M&A Group. He concentrates his practice on the life science industry, providing general corporate representation to a wide range of companies, from start-ups and emerging growth companies to large public companies. He also regularly represents venture capital and private equity funds, as well as biotechnology and pharmaceutical companies, in a variety of mergers and acquisitions, venture and growth equity financings, licensing, collaborations, joint ventures and other strategic transactions. Proskauer is a leading global law firm focused on creating value. Founded in 1875 in New York City, Proskauer has over 700 lawyers active in virtually every major market worldwide and is widely recognized not only for legal excellence but also for dedication to client service.

              Investor Contact

              Ashley Robinson
              LifeSci Advisors, LLC
              Email: ir@lifesciadvisors.com

              View all

              Email Alerts

              Automatically receive Altimmune, Inc. financial information by e-mail

              Learn more